DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based studyECCO'20 Vienna 2020
1
DOP19: Real-world healthcare resource utilisation among patients with Inflammatory Bowel Disease administered vedolizumab for 6 monthsECCO'20 Vienna 2020
1
DOP20: Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicineECCO'20 Vienna 2020
1
DOP21: Time to first treatment with biologic agents for Ulcerative Colitis and Crohn’s Disease across four Nordic countries: Results from the TRINordic studyECCO'20 Vienna 2020
1
DOP22: Certification of Integral Care IBD Units: Evaluation of a certification program (CUE)ECCO'20 Vienna 2020
1
DOP25: Medication use and comorbidities among elderly as compared to younger patients with Inflammatory Bowel Disease in the TARGET-IBD CohortECCO'20 Vienna 2020
1
DOP26: Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s DiseaseECCO'20 Vienna 2020
1
DOP27: Transanal minimally invasive surgery (TAMIS) – A noval approach for treatment of pouch failureECCO'20 Vienna 2020
1
DOP28: Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s Disease: A pilot serum proteomic analysis of the PANTS cohortECCO'20 Vienna 2020
1
DOP30: Multi-‘omics profiling in patients with quiescent Inflammatory Bowel Disease identifies biomarkers predicting relapseECCO'20 Vienna 2020
1
DOP33: Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of Ulcerative ColitisECCO'20 Vienna 2020
1
DOP34: Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulasECCO'20 Vienna 2020
1
DOP35: Monitoring of mucosal T cells subsets under biotherapies in IBD: Responders exhibit a phenotype similar to healthy controlsECCO'20 Vienna 2020
1
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort StudyECCO'20 Vienna 2020
1
DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologicsECCO'20 Vienna 2020
1
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort studyECCO'20 Vienna 2020
1